Recruiting Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812 Conditions Abemaciclib, Breast Adenocarcinoma, Breast Cancer, +46 more Locations Centro di Riferimento Oncologico IRCCS — Aviano, Italy Azienda Socio Sanitaria Territoriale degli Spedali Civili — Brescia, Italy Humanitas Istituto Clinico Catanese — Catania, Italy ASST Lariana - Ospedale Sant'Anna — Como, Italy View all 24 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer NCT02333370 Conditions Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Locations Novartis Investigative Site — Hong Kong Novartis Investigative Site — Nagoya, Aichi-ken, Japan Novartis Investigative Site — Sapporo, Hokkaido, Japan Novartis Investigative Site — Yokohama, Kanagawa, Japan View all 15 locations View more locations Show fewer locations Loading locations... View Trial Details
